ArticleCardiovascular diabetology2021

Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON.

Alberto J Lorenzatti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.